Senators Press US FDA For Faster Approval Of Generic Insulin

Bipartisan group wants more flexibility for pending applications during NDA-to-BLA transition; Lilly's authorized generic of Humalog suggests political pressure on insulin pricing is having an impact. 

Washington DC Capitol dome detail with waving american flag

A bipartisan group of senators are asking the US FDA to make it easier for sponsors to develop generic versions of insulins even as the agency transitions regulation of the products from the NDA to BLA framework.

The letter (sent by Sens. Dick Durbin, D-Ill., Kevin Cramer, R-N.D., Tina Smith, D-Minn., and Bill Cassidy, R-La.) underscores...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access